PPT-FIRST-LINE EGFRm+ NSCLC PATIENT CASE STUDY

Case study 9 Provided by Dr Qamar Ghafoor Clinical Oncology Consultant University Hospital Birmingham TAGRISSO osimertinib Prescribing Information for Great Britain may be found here. Brada. . Torino. . 6 March 2015. Perspectives in lung cancer. . Stereotactic ablative radiation therapy (. SABR). in patients with inoperable NSCLC. SABR in the context of modern radiotherapy of . Ranee Mehra, MD. Fox Chase Cancer Center. Philadelphia, PA. Disclosures. Consulting – Novartis, Bristol Myers Squib. Spouse is employee of GSK. Acknowledgment: J. Weiss. Ras-Raf-MEK-ERK1/2 MAP . kinase. Le Chevalier, . MD. The Role of Translational Research . in . NSCLC. Outline of Talk. The importance of translational research in improving treatment of NSCLC. Key remaining unmet needs. Overview of promising approaches/agents in the future treatment of NSCLC . of the expression of . 17-beta-hydroxysteroid . dehydrogenases. . type 1 and type 2 . in non-small cell lung cancer. Paweł Jagodziński. Hanna . Drzewiecka. ; M.Sc.. Ph. . D. student. Department of . Jared Weiss, MD . Assistant . Professor of Medicine . Division . of Hematology and Oncology . University . of North Carolina School of Medicine . Attending Physician. UNC . Lineberger. Comprehensive Cancer . Dr Tan . Jiunn. Liang. Clinical Specialist (Respiratory Medicine). Department of Medicine. Universiti. Malaya Medical Centre. Disclaimer. This program is provided as a service to the medical profession and represents the opinions of the speakers, not necessarily those of Merck or MSD or its affiliates. CW – adult male presenting with severe pain in the left shin, the ankle joint is twisted at an unnatural angle. He has been doing gymnastics, and landed badly while performing a double somersault. . The Role of Antiangiogenic Agents in the Changing Treatment Paradigm of NSCLC: Expert Perspectives Moderator Solange Peters, MD, PhD Chair, Medical Oncology Department of Oncology Centre Hospitalier Universitaire Vaudois (CHUV) The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature Manel Esteller , MD, PhD. Director, Josep Carreras Leukaemia Research Institute (IJC) Director, Cancer Epigenetics and Biology Program (PEBC) proceedings from the live CME event and may include . the use of trade names and other raw, unedited content. . Moderator. Neil Love, MD. Faculty . Oncology Grand Rounds. . Emerging Strategies in Non-Small Cell Lung Cancer. . 5. th. most commonly diagnosed cancer in Australia. 8.9% of new cancer diagnoses. In 2009: . 10,193 cases (. 6034 . men, 4159 women). Projection to . 2020.  . 13,640. Mortality. In 2010 most common cause of cancer death. Addressing Practical Clinical Questions Across the Metastatic Lung Cancer Continuum. Friday, October 11, 2019. 6:15 PM – 7:45 PM . Chicago, Illinois. Faculty. . Moderator. Joel W Neal, MD, PhD. Nasser H Hanna, MD. Optimal Management of Metastatic . Non-Small Cell Lung Cancer. Faculty. . Moderator. Neil Love, MD. Hossein . Borghaei. , DO, MS . Julie R . Brahmer. , MD. Edward B . Garon. , MD, MS. Ramaswamy Govindan, MD. Intervista a Federico . Cappuzzo. Background:. Programmed death-ligand 1 (PD-L1) expression on tumor cells (TC) or tumor-infiltrating immune cells (IC) is associated with OS, PFS and ORR in pts with advanced NSCLC treated with atezolizumab (anti-PDL1, MPDL3280A; Spigel et al, Spira et al, ASCO 2015), indicating that PD-L1 expression on both TC and IC is important for anti-tumor immunity. However, these 2 distinct expression patterns suggest the existence of previously unidentified NSCLC subtypes with distinct immunologic profiles. .